New therapeutics strategies in renal cell carcinoma

被引：1
|
作者：
Meric, J. -B. [1 ]
Billemont, B. [2 ]
Rixe, O. [3 ]
机构：
[1] Ctr Med Bligny, Dept Oncohematol, F-91640 Briis Sous Forges, France
[2] Hop Cochin, AP HP, Ctr Etud & Recours Inhibiteurs Angiogenese, F-75014 Paris, France
[3] Univ Cincinnati, Barrett Canc Ctr, Cincinnati, OH USA
来源：
BULLETIN DU CANCER | 2010年 / 97卷
关键词：
renal cell carcinoma; angiogenesis; targeted therapy; VEGF; immunotherapy; axitinib; HEDGEHOG SIGNALING PATHWAY; TIE2-EXPRESSING MONOCYTES; TUMOR ANGIOGENESIS; CANCER; NEUROPILIN-1; HYPOXIA; GROWTH; ACTIVATION; INHIBITORS; GENETICS;
D O I：
10.1684/bdc.2010.1070
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
New medical strategies have emerged over the past decade for the treatment of advanced renal cell carcinoma based on the discovery of specific molecular abnormalities. However, molecular targeted therapeutics including anti-angiogenics have demonstrated significant limits ( limited impact on overall survival, development of potential severe toxicities). We review the future directions for drug development based on specific interaction with cellular and extra-cellular pathways. Both von Hippel-Lindau alterations and high immunogenicity profile represent two remarkable characteristics identified in clear cell carcinoma. The new generation of anti-angiogenics ( including HIF, Notch, or angiopoietin inhibitors) and recent developments in immunotherapy also provide opportunities to modify the prognosis of advanced renal cell carcinoma.
引用
收藏
页码：S53 / S63
页数：11
相关论文
共 50 条
  • [41] Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma: Challenges and Opportunities
    Mahmoud, Ahmed M.
    Nabavizadeh, Reza
    Rodrigues Pessoa, Rodrigo
    Garg, Ishita
    Orme, Jacob
    Costello, Brian A.
    Cheville, John
    Lucien, Fabrice
    ONCOLOGIST, 2023, : 297 - 308
  • [42] Breaking through a Plateau in Renal Cell Carcinoma Therapeutics: Development and Incorporation of Biomarkers
    Pal, Sumanta Kumar
    Kortylewski, Marcin
    Yu, Hua
    Figlin, Robert A.
    MOLECULAR CANCER THERAPEUTICS, 2010, 9 (12) : 3115 - 3125
  • [43] The intersection of sunitinib with the immunosuppressive microenvironment of renal cell carcinoma: implications for future therapeutics
    Renee N. Salas
    James H. Finke
    Brian I. Rini
    Targeted Oncology, 2007, 2 : 225 - 234
  • [44] Advances in treatment strategies for non–clear cell renal cell carcinoma
    Shangwei Li
    Liangyou Gu
    Xin Ma
    Xu Zhang
    Oncology and Translational Medicine, 2024, 10 (05) : 206 - 211
  • [45] Immunotherapy for renal cell carcinoma: New therapeutic combinations and adverse event management strategies: A review
    Ma, Xiaohan
    Chen, Jibing
    Chen, Sheng
    Lan, Xuan
    Wei, Zengzhao
    Gao, Hongjun
    Hou, Encun
    MEDICINE, 2024, 103 (30)
  • [46] Novel strategies and therapeutics for the treatment of prostate carcinoma
    Morris, MJ
    Scher, HI
    CANCER, 2000, 89 (06) : 1329 - 1348
  • [47] Current discovery strategies for hepatocellular carcinoma therapeutics
    Dai, Qiuzi
    Zhang, Cunlong
    Yuan, Zigao
    Sun, Qinsheng
    Jiang, Yuyang
    EXPERT OPINION ON DRUG DISCOVERY, 2020, 15 (02) : 243 - 258
  • [48] Treatment Strategies in Metastatic Renal Cancer: Dose Titration in Clear Cell Renal Cell Carcinoma
    Brown, Janet E.
    Symeonides, Stefan N.
    EUROPEAN UROLOGY, 2022, 82 (03) : 293 - 294
  • [49] Clear cell papillary renal cell carcinoma: A new distinct entity or subtype of clear cell renal carcinoma
    Deml, K. -F.
    Schildhaus, H. -U.
    Comperat, E.
    Schraml, P.
    Storz, M.
    von Teichmann, A.
    Bonventre, J.
    Moch, H.
    VIRCHOWS ARCHIV, 2014, 465 : S5 - S5
  • [50] The molecular characterization and therapeutic strategies of papillary renal cell carcinoma
    Chen, Qiwei
    Cheng, Liang
    Li, Quanlin
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (02) : 169 - 175
12345